These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37084480)

  • 21. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
    Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
    Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice.
    Merry TL; Tran M; Dodd GT; Mangiafico SP; Wiede F; Kaur S; McLean CL; Andrikopoulos S; Tiganis T
    Diabetologia; 2016 Dec; 59(12):2632-2644. PubMed ID: 27628106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism.
    De Nardo W; Miotto PM; Bayliss J; Nie S; Keenan SN; Montgomery MK; Watt MJ
    Mol Metab; 2022 Jun; 60():101491. PubMed ID: 35381388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals.
    Haufe S; Engeli S; Kaminski J; Witt H; Rein D; Kamlage B; Utz W; Fuhrmann JC; Haas V; Mähler A; Schulz-Menger J; Luft FC; Boschmann M; Jordan J
    Nutr Metab Cardiovasc Dis; 2017 Oct; 27(10):858-864. PubMed ID: 28958691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
    Li T; Huang X; Yue Z; Meng L; Hu Y
    Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Branched Chain Amino Acids Cause Liver Injury in Obese/Diabetic Mice by Promoting Adipocyte Lipolysis and Inhibiting Hepatic Autophagy.
    Zhang F; Zhao S; Yan W; Xia Y; Chen X; Wang W; Zhang J; Gao C; Peng C; Yan F; Zhao H; Lian K; Lee Y; Zhang L; Lau WB; Ma X; Tao L
    EBioMedicine; 2016 Nov; 13():157-167. PubMed ID: 27843095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism and therapeutic strategy of hepatic
    Li ZY; Wu G; Qiu C; Zhou ZJ; Wang YP; Song GH; Xiao C; Zhang X; Deng GL; Wang RT; Yang YL; Wang XL
    World J Gastroenterol; 2022 Jul; 28(25):2937-2954. PubMed ID: 35978872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
    Vergani L
    Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploratory Data Analysis of Cell and Mitochondrial High-Fat, High-Sugar Toxicity on Human HepG2 Cells.
    Amorim R; Simões ICM; Veloso C; Carvalho A; Simões RF; Pereira FB; Thiel T; Normann A; Morais C; Jurado AS; Wieckowski MR; Teixeira J; Oliveira PJ
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
    Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
    Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
    Brachs S; Winkel AF; Tang H; Birkenfeld AL; Brunner B; Jahn-Hofmann K; Margerie D; Ruetten H; Schmoll D; Spranger J
    Mol Metab; 2016 Nov; 5(11):1072-1082. PubMed ID: 27818933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
    Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
    Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
    Ma R; Zhan Y; Zhang Y; Wu L; Wang X; Guo M
    Drug Dev Res; 2022 May; 83(3):735-744. PubMed ID: 34927282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
    Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
    Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA controls hepatic lipid metabolism by regulating the NRF2 signaling pathway.
    Huang B; Xiong X; Zhang L; Liu X; Wang Y; Gong X; Sang Q; Lu Y; Qu H; Zheng H; Zheng Y
    J Mol Cell Biol; 2021 Oct; 13(7):527-539. PubMed ID: 34048566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.